about
In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissuesIQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistanceA phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerSmall molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathwaysAutophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumabCrystal Structure of a Human Single Domain Antibody Dimer Formed through VH-VH Non-Covalent InteractionsPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceInduction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancert-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer CellsTranslational imaging endpoints to predict treatment response to novel targeted anticancer agents.t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.Novel decapeptides that bind avidly and deliver radioisotope to colon cancer cellsAlternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysisAdo-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastorisIntegrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer.HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRKPersistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transferThe combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityThe role of HER2 in cancer therapy and targeted drug deliveryHER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarityVaccines and immunotherapeutics for the treatment of malignant diseaseThe Met oncogene and basal-like breast cancer: another culprit to watch out for?The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer.Treating breast cancer in the 21st century: emerging biological therapiesThe epidermal growth factor receptor family in breast cancer.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatmentMitochondrial DNA somatic mutation in cancer
P2860
Q24294917-984D4AFC-AD8E-4233-B545-C23221FD47DAQ24309891-5FF50834-C5D5-47D9-8A90-3919E121327FQ24594725-21DA4718-00F3-415D-BDB8-1FDC0EA3B5E8Q26785612-EBCB782A-F5D5-4F2F-A7EB-DCA8A4D112EBQ27317155-476E3D97-363E-426A-996B-812354936025Q27346475-9A751AAA-6265-422D-AA61-A0B8573B2763Q27676789-4E5458B3-74C6-4B14-BD1D-C2E593EDA9C2Q27851691-3181C269-4798-45C2-B436-E264981AB812Q27851975-40C647AE-F173-481A-9A8D-12FBC8CB789EQ28077347-689E6DE2-3B05-4680-B7C1-F7D12A712394Q28534358-52C95445-EE66-4457-AF3E-41C5F10DD3E0Q28545954-535511A0-72AA-4ED5-A3EF-FC2D38081884Q30465097-CED87CD0-4442-4E84-9D8D-8D681E50DFCCQ30862407-971B0F26-956C-41CF-894D-9EF364EBDC84Q33301319-A13DD6D7-4ED6-43AB-B65E-33F802F15D1CQ33330736-00263151-FF33-4FAB-825C-DB96A0D0D590Q33378824-E34E9472-B309-42EC-8049-C5E06DE1E3EBQ33414335-86822A9A-E939-44F9-8880-607AD1ECC005Q33492560-3706946D-2F37-4F33-83DC-2C76951A05BDQ33517983-B7BFDAE2-6EA4-45AA-9FFD-BFCC69FD2C46Q33618553-3C88B295-A9CC-4A64-B77B-0A38DF2265DBQ33626569-68B679E8-4A02-4E6F-BF62-F1C705BDBB66Q33870552-ACD37BE0-BA93-4EC9-BBB9-398DAB9BAE0CQ33912469-AF0C6CE6-CE66-4111-BD53-6709854CF1B9Q34005560-DCC352B9-4083-408A-9297-4E140947ED5EQ34036041-FF8B4D70-0018-4235-94BE-D8DEA9A70300Q34054213-F198F234-3D6C-4964-8A36-B7DEC9DC0989Q34111958-F49B34CD-3BF8-4CFC-8A2A-94709FE976F6Q34169164-BF629EB6-B9CF-4FCD-A2CE-B53C14BE89FCQ34170074-232A04D5-0D87-4369-B63D-A7A0175B5CCDQ34173500-E5E513E7-A7FF-4E9C-BACA-C00E46872B4BQ34286419-CD1F17E7-BE40-42D7-BE72-0123819A4EB3Q34326536-647F170D-C553-481F-BF83-0DBDD51DEEBAQ34363400-93843B0D-703D-4918-B9A4-B75E7DD27928Q34363419-DE462F55-F26C-4A00-B3E6-08AAF92A5F20Q34374096-CC8F1983-CED2-42CE-8103-059F99D930B0Q34433064-6C1CF6D2-BDA9-42AD-8604-11E9F81AA646Q34524533-BB0C8867-098C-414B-B893-23F092101E8CQ34694211-273FB123-E083-4937-9E0D-DBCF1F6E050EQ34906440-A8CD7CB6-A932-4284-8550-2BF2A656EF62
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Trastuzumab: triumphs and tribulations.
@en
type
label
Trastuzumab: triumphs and tribulations.
@en
prefLabel
Trastuzumab: triumphs and tribulations.
@en
P2860
P356
P1433
P1476
Trastuzumab: triumphs and tribulations.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210379
P407
P577
2007-05-01T00:00:00Z
P5875
P6179
1052849615